Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck Purchases 40,000 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck purchased 40,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was purchased at an average price of $1.40 per share, with a total value of $56,000.00. Following the completion of the transaction, the director now owns 2,606,879 shares of the company’s stock, valued at approximately $3,649,630.60. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Biodesix Trading Down 0.7 %

Shares of Biodesix stock opened at $1.33 on Thursday. The business has a 50-day moving average price of $1.70 and a 200-day moving average price of $1.61. Biodesix, Inc. has a twelve month low of $1.15 and a twelve month high of $2.21. The firm has a market cap of $193.47 million, a price-to-earnings ratio of -3.41 and a beta of 1.22. The company has a quick ratio of 3.28, a current ratio of 3.28 and a debt-to-equity ratio of 0.99.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 369.89%. The company had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. Equities research analysts anticipate that Biodesix, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. AIGH Capital Management LLC raised its position in Biodesix by 74.0% during the second quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock valued at $8,843,000 after purchasing an additional 2,458,727 shares during the period. Perceptive Advisors LLC bought a new position in Biodesix during the second quarter valued at $3,326,000. Farallon Capital Management LLC purchased a new stake in Biodesix in the 2nd quarter worth about $2,874,000. Perkins Capital Management Inc. boosted its position in shares of Biodesix by 74.7% during the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after buying an additional 310,000 shares during the period. Finally, CVI Holdings LLC purchased a new stake in shares of Biodesix in the second quarter worth approximately $59,000. Institutional investors own 20.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Craig Hallum assumed coverage on Biodesix in a research note on Friday, July 26th. They issued a “buy” rating and a $3.00 price target for the company. Scotiabank initiated coverage on Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.